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Introduction: Venous thromboembolism (VTE) requires urgent diagnosis and treatment to avoid related
complications. Clinical presentations of VTE are nonspecific and require definitive confirmation by imaging
techniques. A clinical pretest probability (PTP) score system helps predict VTE and reduces the need for costly
imaging studies. D-dimer (DD) assay has been used to screen patients for VTE and has shown to be specific for VTE.
The combined use of PTP and DD assay may improve exclusion of VTE and safely avoid imaging studies.
Materials and methods: We prospectively used the Wells PTP score and a DD test to evaluate 230 consecutive
patients who presented with VTE symptoms. The receiver operating characteristic curve was used to identify a new
DD cutoff value, which was applied to VTE diagnosis and compared with the upper limit of locally established
reference range for prediction of thrombosis alone and in combination with the clinical PTP score.
Results: We evaluated 118 patients with VTE symptoms fulfilling the inclusion criteria, 64 (54.2%) with clinically
suspected deep vein thrombosis (DVT) and 54 (45.8%) with symptoms of pulmonary embolism (PE). The PTP was
low in 28 (43.8%) and moderate/high in 36 (56.25%) of the suspected DVT patients, and low in 29 (53.7%) and
moderate/high in 25 (46.3%) of the suspected PE patients. Eighteen cases were confirmed by imaging studies: 9
DVT and 9 PE. The agreement between confirmed cases and PTP was significant with PE but not DVT. The negative
predictive value for both DVT and PE with current DD cutoff value of <250 μg/L DDU was 100%, whereas with the
calculated cutoff the NPV was 88%.
Conclusions: We confirm that PTP score is valuable tool for medical residents to improve the detection accuracy of
VTE, especially for PE. The DD cutoff value of 250 μg/L FEU is ideal for excluding most cases of low PTP; however,
the calculated cutoff was less specific for the exclusion of VTE.
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Deep vein thrombosis (DVT) and pulmonary embolism
(PE) are common presentations of venous thromboem-
bolism (VTE) that require urgent recognition, diagnosis,
and treatment to prevent or minimize the risk of throm-
boembolic complications and avert the exposure of pa-
tients without thrombosis to the risks of anticoagulant
therapy and associated morbidity and mortality [1]. Al-
though the clinical symptoms and signs such as dyspnea,
pleuritic chest pain, tachypnea, and tachycardia can raise
suspicion of PE, and symptoms and signs of swollen,
red, tender, and hot lower limbs can raise suspicion of
DVT, these are nonspecific and need to be confirmed by
further diagnostic and costly imaging techniques [2].
Wells established a clinical prediction rule incorporating
signs, symptoms, and risk factors that can accurately be
applied to categorize probability for DVT or PE as low,
moderate, or high [3]. A recent article suggested that
this approach could be further simplified by using only 2
risk categories: DVT unlikely and DVT likely [1]. The
Haemostasis and Thrombosis Task Force of the British
Committee for Standards in Haematology [4] recom-
mends that to eliminate the need for diagnostic imaging,
a combination of D-dimer (DD) assay and pretest prob-
ability (PTP) score should give a negative predicative
value (NPV) of >98%, which is equivalent to that of com-
pression ultrasonography for proximal DVT [5].
Unfortunately, a lung scan is often nondiagnostic, even
when the incidence of PE ranges from 10% to 30%, and
necessitates further investigations. The PTP score for PE
in low, moderate, and high groups has been reported to
be 1.3%, 16.2%, and 37.5%, respectively [6]. The imaging
techniques are costly and operator-dependent, with vari-
ability in sensitivity that can be <73% in cases of distal
DVT [2].
Activation of the coagulation system results in forma-
tion of fibrin, which (after being cross-linked by factor
XIII) results in a fibrin clot that is subsequently lysed by
the activation of the fibrinolytic system, which breaks
the fibrin clot to fibrin degradation products. DD is a
fibrin-derived fragment that is released into the circulation
when cross-linked fibrin is broken down by the fibrinolytic
system [7,8]. Recently, the DD assay has gained signifi-
cance as a tool that helps in clinical decisions about the
presence of thrombosis. It is generally accepted that clin-
ical assessment and elevated DD levels have further diag-
nostic advantages, enabling administration of therapy
when imaging is not available [9]. On the other hand, sev-
eral studies have shown that the DD assay may have a
high NPV [9-11].
Different techniques are available for DD level meas-
urement, but many lack precision. Enzyme-linked im-
munosorbent assay (ELISA) continues to be the gold
standard for DD level measurement with high sensitivity,but is time-consuming and lacks specificity [8]. New im-
munological techniques such as immunoturbidimetry
have gained attention because of their high sensitivity
(around 98%) with intermediate specificity (better than
ELISA) and short process time [12]. The introduction of
Point of Care Testing helped further decrease turn-
around time; however, poor bioequivalence hampered its
use in clinical settings [13]. Both the PTP scoring system
and DD assay has resulted in better decision-making
and early thrombosis diagnosis [1,14].
In this study, we evaluated the usefulness of PTP scor-
ing system and DD assay as diagnostic tools for front-
line clinicians (medical residents) to detect thrombosis
in patients presenting with VTE symptoms.
Materials and methods
Patients
Over 3 years, a group of senior medical residents pro-
spectively assessed all inpatients and outpatients >18
years of age who presented with suspected PE or DVT
for enrollment in this study. Patients were excluded if
they had any of the following: 1) a history of venous
thrombosis (6 months), 2) recent pelvic surgery (1
month); 3) an indwelling central line; 4) current preg-
nancy or delivery <6 weeks prior; 5) inability to undergo
compression ultrasonography because of physical or
technical limitations; 6) contraindication for radio-
logical contrast; 7) a terminal illness with a life expect-
ancy of <3 months; 8) Patients with active cancer; and
9) symptoms that resolved <72 h before presentation.
The research committee of King Faisal Specialist Hospital
and Research Center, Riyadh, Saudi Arabia had approved
this study.
Clinical evaluation
A senior medical resident evaluated all patients clinically
at presentation. A data collection form including exclu-
sion criteria, signs, and symptoms included by Wells
PTP for DVT and PE was used (Tables 1 and 2) [1,15].
Regardless of the PTP score, patients underwent the ap-
propriate imaging technique and a sample was collected
for DD testing.
DD testing
Venous blood was collected by clean venipuncture into
3.2% sodium citrate to a final ratio of 9:1 using Vacutai-
ner tubes (Becton Dickinson, Franklin Lakes, NJ, USA).
Each specimen was centrifuged for 10 min at 3000 rpm
in a refrigerated centrifuge and plasma was drawn into a
clean plastic or polystyrene (12 × 75 mm) tube and
stored at 4°C until testing with 24 hr. from collection.
DD level was tested using Innovance DD (Dade Behring,
Marburg, A Siemens Company, Germany)—which is a
latex-enhanced, turbidimetric test based on polystyrene
Table 1 Clinical model for predicting the pretest
probability score of deep vein thrombosis (adapted from
Wells et al. [1])
Clinical characteristics Score
Active cancer (patient receiving treatment for cancer within the
previous 6 months or currently receiving palliative treatment)
1
Paralysis, paresis, or recent plaster immobilization of the lower
extremities
1
Recently bedridden for ≥3 days or major surgery within the
previous 12 weeks requiring general or regional anesthesia
1
Localized tenderness along the distribution of the deep venous
system
1
Entire leg swollen 1
Calf swelling at least 3 cm larger than that on the asymptomatic
side (measured 10 cm below the tibial tuberosity)
1
Pitting edema confined to the symptomatic leg 1
Collateral superficial veins (nonvaricose) 1
Previously documented deep vein thrombosis 1
Alternative diagnosis at least as likely as deep vein thrombosis −2
A score of ≥2 indicates that the probability of deep vein thrombosis is likely;
a score of >2 indicates that the probability of deep vein thrombosis is unlikely.
In patients with symptoms in both legs, the leg with more symptoms is used.
(Low: 0–1; moderate: 1–2; high: ≥2–3).
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(DD5) to the cross-linkage region of cross-linked fibrin
degradation products. All samples were tested by BCS
Instruments from Siemens (Marburg, Germany). The
local reference range was established from 20 normal
blood bank donors (25–250 μg/L FEU). All patients had
been subjected to radiological studies, Compression
ultrasonography for DVT and CT- pulmonary angiog-
raphy for PE.Table 2 Rules for predicting the probability of pulmonary




Clinical signs and symptoms of deep venous thrombosis 3.0
An alternative diagnosis deemed less likely than pulmonary
embolism
3.0
Heart rate >100 beats/min 1.5
Immobilization or surgery in the previous 4 weeks 1.5
Previous deep venous thrombosis or pulmonary embolism 1.5
Hemoptysis 1.0







Frequency and percentage were used to describe data ac-
cording to different demographic variables, diagnostic
tests, and outcomes for both DVT and PE. Kappa statis-
tic was used to test the agreement between clinical pre-
test and radiological findings. To obtain the DD cutoff
value to rule out DVT and PE, a constructed receiver
operating curve (ROC) curve was used considering ac-
tual DD results and radiology as the gold standard. The
agreement between the new cutoff value and radiology
was obtained by the McNemar test. Sensitivity, NPV,
specificity, positive predictive value (PPV), and likeli-
hood ratios were calculated on the basis of the diagnos-
tic imaging. P <0.05 was considered significant for all
statistical tests. SPSS 20 and Excel 2007 were used for
data analysis.
Results
Of the 230 patients screened during the study enroll-
ment, only 118 fulfilled the inclusion criteria and were
included in the analysis. There were 73 (61.9%) women
and 45 (38.1%) men with a mean age at presentation of
52.64 years (range, 17–108 years). The main reasons for
exclusion were cancer, an indwelling central line, and
pregnancy. The overall prevalence of VTE in this cohort
of patients was 15.3% (18): 9 DVT and 9 PE.
Based on the PTP score, 64 patients (54.2%) were clin-
ically suspected to have DVT. The most common pres-
entation was a swollen limb in 51 (78.5%) and lower
limb pain in 17 (26.2%). Fifty-four (45.8%) were clinically
suspected to have PE, with the most common clinical
presentations being dyspnea in 42 (77.8%), tachycardia
in 14 (25.9%), tachypnea in 14 (25.9%), and pleuritic
chest pain in 13 (24.1%). The PTP score of suspected
DVT patients (n = 64) was found to be low in 28
(43.8%) and moderate to high in 36 (56.2%), whereas in
suspected PE patients (n = 54), it was found to be low in
29 (53.7%) and moderate to high in 25 (46.3%). The inci-
dence of DVT in patients in low and moderate-to-high
PTP score was 7.1% and 19.4% respectively, while for PE
the incidence was 36% in moderate-to-high PTP score.
The agreement between PTP score and radiology results
for VTE in total (DVT &PE) was significant (P <0.01) with
sensitivity 88%, specificity 55%, PPV 26%, and NPV 96%.
However, sub analysis for DVT and PE showed that it was
not significant for suspected DVT (P = 0.160) and sig-
nificant for suspected PE patients (P <0.01), because all
patients with PE who had been confirmed positive by
radiology scored moderate-to-high PTP.
We evaluated the diagnostic value of the established
upper limit of the local reference range (<250 μg/L FEU)
alone against radiology results in patients presenting
with symptoms suggestive of DVT or PE. There were
96/118 (81.8%) cases with positive DD but only 18/96
Figure 1 ROC curve to establish a new cutoff by measured DD
and radiology results.
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tivity, specificity, PPV and NPV was 100%, 22%, 19% and
100% respectively. We assessed the combination of ne-
gative DD (<250 μg/L FEU) with PTP score against radi-
ology, 22/118 (18.6%) patients were found not to have
VTE regardless of the PTP score (Table 3). This is al-
most the same as using DD result alone.
An ROC curve plotted using the measured DD levels
and imaging results was applied to establish a new cut-
off value as the point with the highest sum of sensitivity
and specificity (60% +63%) for detecting patients with
thrombosis (Figure 1). The area under the curve rep-
resents the probability that the assay result for a ran-
domly chosen positive case will exceed the result for a
randomly chosen negative case. The asymptotic signi-
ficance is <0.05, which means that results obtained
using the assay were better than those obtained without
using it.
The calculated DD cutoff value was 815 μg/L FEU for
both DVT and PE. To test the accuracy of the calculated
cutoff, we used the McNemar test. Considering radio-
logy as the gold standard, we found that the calculated
cutoff alone had sensitivity, specificity, PPV and NPV as
88%, 58%, 19%, and 88% respectively. The combination
of negative calculated DD cutoff (<815 μg/L FEU) with
PTP score identified (56%) 66/118 cases with negative
calculated DD in which (88%) 58/66 confirmed negative
by radiology and (12%) 8/66 were confirmed positive by
radiology (Table 4). These results show that increase in
the cutoff of DD showed improvement in PPV with sig-
nificant reduction in the NPV.
Discussion
The evaluation of patients with VTE has been improved
by the introduction of standardized probability scoring
systems. Different PTP scoring systems have been intro-
duced and evaluated for VTE detection sensitivity and
specificity and minimizing the need for radiological con-
firmation [16-18]. Several studies have investigated PTP
score assessment in patients with suspected VTE [19-22].
Wells et al developed a score system calculated from
clinical and historical data to stratify patients into low,Table 3 The combination of the negative current DD










Test with current cutoff (DD
negative with high PTP score)
0 7 (30%) 7 (30%)
Test with current cutoff (DD
negative with Low PTP score)
0 15 (70%) 15 (70%)
Total 0 22 (100%) 22 (100%)moderate, and high risk of DVT [3]. Other studies have
looked at the significance of the value of these PTP sys-
tems in predicting PE [23,24]. The use of DD, the pre-
dominant form of a fibrin-degradation product, as a
biomarker of thrombosis had been extensively eval-
uated clinically in the past several decades [11]. DD
sensitivity and specificity were the limiting factors for
using this test to evaluate thrombosis. Several studies
have shown that ELISA is the most sensitive, but with
moderate specificity and high NPV; however, it is been
hampered by the impracticality of the time needed to
perform [8,11]. Many other techniques are available for
DD level testing that differ in the principal type of mo-
noclonal antibody specificity that recognizes different
epitopes, assay calibration standards, and instrumentation.
However, each of these methods has its own limitationsTable 4 Combination between negative calculated DD










Test with calculated cutoff
(DD negative with high
PTP score)
8 (12.1%) 25 (37.8%) 33 (50%)
Test with calculated cutoff
(DD negative with low
PTP score)
0 33 (50%) 33 (50%)
Total 8 (12.1%) 58 (87.8%) 66 (100%)
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[25-28].
We used an immunoturbidimetry (Innovance) assay for
measuring DD levels in our hospital. It had been reported
to have high sensitivity and NPV but low specificity [5].
De Moerloose et al. evaluated Innovance on different ana-
lyzers and found it accurate for the VTE diagnosis workup
with a sensitivity >99% and NPV 95.5% [29]. In our study,
we found that the sensitivity and specificity depends on
the selected cutoff value, whereas the reported current
DD cutoff value showed 100% sensitivity and 22% specifi-
city with a NPV of 100% and PPV of 19%. These results
were also reported in several studies with an NPV range
of 91–96% [25,28,29].
Using a different DD level has been shown to produce
a different specificity in excluding VTE. Yamaki et al.
showed that the use of ROC curve analysis to select DD
cutoff points increased the specificity from 48.9% to 78.2%
for the low PTP groups; however, it did not achieve sub-
stantial improvement in the moderate- and high-risk PTP
groups [30]. We did not find improvement in thrombosis
detection by using the ROC curve calculated DD level.
Courtney et al. showed the same findings when they tested
the different DD levels [23]. Although the sensitivity of
most new DD assays, including ours, has been shown to
be very high, the specificity is low even in ELISA-based
assays [2].
The PTP scoring system proposed by Wells was tested
in many studies and was found to be reproducible when
used by junior residents [31] and could be used to ex-
clude VTE safely when the score was low [3].
Combination of both the PTP score and DD test value
has been suggested as sufficiently accurate for the exclu-
sion of VTE and reduction of the requirement for radi-
ology [9-11,14,32,33]. When we combined both PTP
score and DD level to exclude VTE, we identified a low
PTP score in 43.1% and moderate to high PTP score in
56.9% of DVT patients with no significant agreement
with radiological studies; however, 52.7% and 47.3% of
PE patients had a low and moderate-to-high PTP score
respectively, with significant agreement of the low PTP
score with radiological findings. This can be attributed
to more specificity for PE symptoms than for DVT
symptoms. Kelly and Hunt found in a pool of data from
4 different studies that 41%, 49%, and 10% of patients
had low, moderate, or high PTP score with PE preva-
lences of 8%, 36%, and 67%, which is not very different
from our reported results [7].
In conclusion, according to our data, we are certain
that we can rule out thrombosis in patients with nega-
tive DD results when combined with low PTP score;
however, the PTP score is less sensitive for DVT and
cannot rule out patients with thrombosis. There is no
need to change the cutoff value because the cut off weused based on reference range of DD level showed very
high NPV in VTE and the new cutoff value did not con-
siderably improve the PPV alone or in combination with
PTP. Our study has a major limitation, which is its low
sample size; however, the results are in agreement with
those previously reported.
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